Clinical Efficacy of Recombinant Human Endostatin Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer
CAO Jun
WU Lin
Abstract：Objective:To investigate the clinical efficacy of Recombinant Human Endostatin combined with Pemetrexed and Cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC).Method:76 patients with advanced NSCLC in our hospital were randomly divided into the observation group and the control group,38 cases in each group.The cases in the control group only received Pemetrexed and Cisplatin,while the cases in the observation group received administration of Recombinant Human Endostatin treatment on the basis of the above.The clinical efficacy and adverse events of two groups were observed and compared.Result:The total clinical efficiency and clinical benefit rate of the observation group were significantly higher than those of the control group(P<0.05). 1-year survival and median time to progression of the observation group were significantly higher than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The clinical efficacy of Recombinant Human Endostatin combined with Pemetrexed and Cisplatin in the treatment of advanced non-small cell lung cancer are significant,less side effects,which can be applied in clinic.
Keywords：Non-small cell lung cancerRecombinant Human EndostatinPemetrexedCisplatin
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 5-6 )